Regeneus Ltd. (AU:CMB) has released an update.
Cambium Bio Limited, a clinical-stage regenerative medicine company, has merged with Cambium Medical Technologies and raised $3.48 million from shareholders and strategic investors. The merged entity focuses on the development of Elate Ocular®, a treatment for dry eye disease, though Phase 3 studies are unlikely to begin in 2024 as previously expected. The company reported having $16k in cash at the end of the first quarter of 2024.
For further insights into AU:CMB stock, check out TipRanks’ Stock Analysis page.
